BIDMC's Thea Brennan-Krohn, MD, presented the findings Friday, June 21, 2019, at ASM Microbe 2019, the annual meeting of the American Society for Microbiology.

"Few treatment options are available for patients infected withCandida auris, which causes invasive, life-threatening infections, usually in patients who are already critically ill or have compromised immune systems," said Brennan-Krohn, MD, a post-doctoral research fellow in the lab of James E. Kirby, MD, Director of the Clinical Microbiology Laboratory at BIDMC. "It has an alarming propensity to spread from patient to patient and survive on surfaces in rooms, resulting in hospital outbreaks."

First discovered in Japan in 2009,C. aurishas been detected in patients in more than 20 countries and, as of April 2019, has sickened 643 Americans in 11 U.S. states, according to the U.S. Centers for Disease Control and Prevention (CDC). At present, most cases ofC. aurisare resistant to at least one antifungal drug, with about a third impervious to two or more.

In order to identify new treatment approaches forC. auris, Brennan-Krohn and colleagues used a modified inkjet printer -- a method pioneered for rapid and uniform antimicrobial screening in the Kirby lab -- to test three antifungal drugs, one from each of the main classes of antifungals, combined with two antibacterial antibiotics, which by themselves have no activity against fungal infections.

Using the inkjet technology to dispense uniform samples ofC. aurisinto each of the 96 wells in a standard lab testing plate, Brennan-Krohn tested 10 combinations against 10 strains ofC. auris, a painstaking process that would have taken at least 50 hours if done by hand. It took less than two hours in total using the inkjet dispenser for Brennan-Krohn to find three novel combinations of antifungal and antibacterial drugs that demonstrated activity against this insidious new pathogen.

Using a different method known as a time-kill test, Brennan-Krohn showed that two of the antibacterial-antifungal treatments not only preventedC. aurisfrom growing but also succeeded in killing some of the strains tested.

While the drugs have not yet been tested in combination in humans infected withC. auris, all of the drugs Brennan-Krohn evaluated -- the antifungals amphotericin and caspofungin and the antibacterials minocycline and rifampin -- are FDA-approved antibiotics, currently in use patients with a variety of infections. If the drugs' combined power to inhibit or killC. auristhat they demonstrated in the lab is confirmed in studies in humans, it could mean physicians caring for patients withC. aurisinfections already have access to effective treatment options.